Publications by authors named "Colin Gegg"

Claim this Profile
D
Discovery of the Migraine Prevention Therapeutic Aimovig (Erenumab), the First FDA-Approved Antibody against a G-Protein-Coupled Receptor.
Chadwick Terence King, Colin V Gegg, Sylvia Nai-Yu Hu, Hsieng Sen Lu, Brian M Chan

ACS Pharmacol Transl Sci· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3.
Justin K Murray, Yi-Xin Qian, Benxian Liu, Robin Elliott, Jennifer Aral, Colin V Gegg

J Med Chem· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptide antagonists of the calcitonin gene-related peptide (CGRP) receptor with improved pharmacokinetics and pharmacodynamics.
Les P Miranda, Licheng Shi, Jerry R Holder, Marie Wright, Colin V Gegg

Biopolymers· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptibodies: A flexible alternative format to antibodies.
Grant Shimamoto, Colin Gegg, Tom Boone, Christophe Quéva

MAbs· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor.
Michael P Hall, Colin Gegg, Kenneth Walker, Christopher Spahr, Robert Ortiz

AAPS J· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role.
Balaji Agoram, Ken Aoki, Sameer Doshi, Colin Gegg, Graham Jang

J Pharm Sci· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An acyl-ghrelin-specific neutralizing antibody inhibits the acute ghrelin-mediated orexigenic effects in mice.
Shu-Chen Lu, Jing Xu, Narumol Chinookoswong, Shuying Liu, Shirley Steavenson, Colin Gegg

Mol Pharmacol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor.
Les P Miranda, Jerry Ryan Holder, Licheng Shi, Brian Bennett, Jennifer Aral, Colin V Gegg

J Med Chem· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.
Les P Miranda, Katherine A Winters, Colin V Gegg, Ankita Patel, Jennifer Aral

J Med Chem· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interactions between PEG and type I soluble tumor necrosis factor receptor: modulation by pH and by PEGylation at the N terminus.
Bruce A Kerwin, Byeong S Chang, Colin V Gegg, Margherita Gonnelli, Tiansheng Li

Protein Sci· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mono-N-terminal poly(ethylene glycol)-protein conjugates.
Olaf Kinstler, Graham Molineux, Michael Treuheit, David Ladd, Colin Gegg

Adv Drug Deliv Rev· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis